Evaxion Biotech A/S (EVAX) Company Overview

What does Evaxion A/S do?

Evaxion A/S is a Danish clinical-stage biotechnology company listed on the Nasdaq Capital Market as EVAX. Its core asset is AI-Immunology, a proprietary computational platform for selecting vaccine targets in cancer and infectious disease. With no approved product or recurring product sales, Evaxion combines an internal pipeline with partnerships that can generate research payments, license fees, milestones, and royalties.

A platform company with a vaccine pipeline

The platform analyzes biological and immune data to select targets likely to trigger useful responses. Evaxion says its models can address more than 100 diseases and identify targets within 24 hours. The AI-Immunology platform supports peptide, DNA, protein, and mRNA modalities rather than one delivery technology.

How does Evaxion make money before product approval?

Evaxion’s revenue is event-driven: collaboration funding, license payments, development or regulatory milestones, potential royalties, and research grants. The platform may be reusable, but accounting revenue appears only when contracts and scientific events permit recognition, making quarterly results inherently uneven.

Which revenue streams have been proven?

The strongest proof is the relationship with Merck & Co., Inc., known as MSD outside the United States and Canada. In September 2025, MSD licensed EVX-B3. Evaxion received $7.5 million and remains eligible for up to $592 million in development, regulatory, and sales milestones plus royalties. MSD funds future development, transferring capital intensity to the partner. Gates Foundation-supported work provides another revenue source. The official partnering overview describes the model.

Why revenue quality remains difficult to forecast

FY2025 revenue was $7.5 million, yet Q1 2026 revenue was zero. The contrast shows that contract timing, not steady customer demand, drives reported revenue. Scientific progress should therefore be analyzed separately from quarterly sales, and contingent milestones should never be treated as guaranteed receivables.

Which pipeline assets matter most?

The pipeline covers personalized oncology, off-the-shelf cancer vaccines, and infectious disease. EVX-01 is the leading clinical asset; EVX-B3 is the main partnership proof because MSD licensed it and assumed future development costs. Earlier programs broaden validation but remain far from late-stage value.

What does EVX-01 show so far?

In the two-year Phase 2 dataset reported in 2025, 12 of 16 patients achieved an objective response, equal to 75%. Four patients achieved complete responses, 92% of responding patients were still responding at 24 months, and 54% deepened their response over time. Tumor reduction was observed in 15 of 16 patients. A later Q1 2026 immunogenicity update said 86% of vaccine targets generated a tumor-specific immune response. The percentages describe different endpoints and analyses, so they should be read together rather than treated as interchangeable.

How should the earlier programs be interpreted?

EVX-03 is a personalized DNA vaccine in preclinical development. EVX-04 is designed as an off-the-shelf vaccine for acute myeloid leukemia. EVX-B1 targets S. aureus; EVX-B2 targets gonorrhea; EVX-B4 targets Group A Streptococcus; and EVX-V1 targets cytomegalovirus. The company’s official pipeline makes the breadth clear. Breadth is useful only if it leads to repeatable validation, partnerships, or clinical advancement. Otherwise, a broad preclinical portfolio can consume management attention without producing near-term cash flow.

What does the latest quarter show?

The latest official period is Q1 2026. The interim report shows cash-funded research: revenue was zero, operating loss was $3.8 million, net loss was $3.6 million, and cash was $18.4 million versus $23.2 million at year-end.

What changed operationally during Q1 2026?

Q1 2026 produced scientific rather than revenue progress. Evaxion completed the final physician visit in the EVX-01 extension, reported 86% target recognition, advanced Gates Foundation-supported polio designs, promoted Birgitte Rønø to CSO and COO, and added Jens Bitsch-Nørhave to the board. Management retained runway guidance into H2 2027.

Why finance income deserves attention

Q1 2026 finance income was $0.3 million versus $2.5 million in Q1 2025. Warrants, derivatives, currency exposure, and financing accounting can make net loss diverge from operating loss. Operating analysis should therefore begin with R&D, G&A, operating loss, and cash movement.

How did Evaxion reach its current strategy?

Evaxion’s development is best understood as a shift from a vaccine-discovery start-up toward a partnership-oriented AI-Immunology platform with selected internal clinical programs. The relevant history is not corporate trivia; each turning point changed either evidence quality, capital requirements, or bargaining power with partners.

1. 2008
   The company was incorporated in Denmark and began operations, establishing the scientific base that later became AI-Immunology.
2. 2014
   The business adopted the Evaxion Biotech name, aligning its identity with vaccine development rather than a single research project.
3. 2021
   Nasdaq listing through an ADS offering expanded access to U.S. biotech capital but introduced public-market dilution and listing-risk exposure.
4. 2023–2024
   MSD entered a discovery collaboration and later secured option rights over infectious-disease candidates, providing external validation of the platform.
5. 2025
   The legal name changed to Evaxion A/S, the Gates Foundation collaboration added polio work, and MSD licensed EVX-B3 for $7.5M plus contingent milestones.
6. Late 2025
   Two-year EVX-01 data supplied the strongest clinical evidence supporting the personalized cancer-vaccine approach.
7. 2026
   The company completed the EVX-01 extension follow-up and scheduled three-year efficacy data for presentation at ESMO Congress 2026.

What did the partnership shift change?

MSD shifted Evaxion toward partner-funded development: a partner can validate targets, pay for rights, and absorb later spending. That lowers capital needs but transfers control over timing. MSD’s December 2025 decision not to exercise the EVX-B2 option shows the trade-off: Evaxion retained the gonorrhea asset, but expected partner funding did not advance.

The next history-defining event is expected to be the EVX-01 three-year Phase 2 readout. Evaxion announced that the data are scheduled for ESMO Congress in Madrid on October 23–27, 2026. The official July 2026 announcement identifies the timing, but the results themselves were not yet public as of July 24, 2026.

What gives AI-Immunology a competitive edge?

Evaxion’s proposed advantage is not merely “using AI.” The platform aims to identify antigens that produce relevant immune responses across multiple vaccine formats. Repeated success in personalized cancer, shared tumor antigens, and infectious pathogens would make it a reusable discovery engine rather than a one-product company.

Where could the moat come from?

A durable moat would require proprietary biological data, algorithms that choose better targets, wet-lab and clinical feedback, and partner relationships that create further validation. The 86% EVX-01 target-recognition result and EVX-B3 license are encouraging evidence, but neither alone proves durable advantage.

Who pressures the company?

Competition includes large pharma, specialist cancer-vaccine developers, AI-enabled biotechs, academic laboratories, and discovery platforms. Larger rivals can fund bigger trials, scale personalized manufacturing, and absorb failures. Evaxion may move quickly, but it depends on partners for late-stage development and commercialization.

Who owns Evaxion stock, and why does it matter?

Evaxion has one ordinary-share class with no superior founder voting rights, and one ADS represents 50 ordinary shares. At December 31, 2025, Merck Global Health Innovation Fund beneficially owned 15.03%, while directors and executives as a group held 4.07%. The result is strategic-shareholder influence without founder control.

What does the ownership table signal?

The latest 2025 Form 20-F reports beneficial ownership using ordinary shares and exercisable warrants. Founder and chief AI officer Andreas Holm Mattsson held 1.52%, and board chair Marianne Søgaard held 1.54%. The low individual percentages mean strategic direction is not protected by a controlling founder vote. Board quality, investor confidence, and access to new equity therefore matter greatly.

How does governance connect to financing?

At the April 2026 annual general meeting, shareholders authorized additional warrant issuance and convertible-loan capacity. About 25.15% of outstanding shares were represented in voting. The AGM filing matters because a pre-revenue biotech company must preserve financing flexibility. That flexibility can extend runway, but warrants, convertibles, and equity programs can dilute existing holders.

How financially strong is Evaxion?

The 2025 annual report shows cash of $23.2 million versus $6.0 million a year earlier, helped by $22.4 million of financing inflow. Revenue rose to $7.5 million from $3.3 million; operating loss narrowed to $9.2 million from $14.7 million; net loss narrowed to $7.7 million from $10.6 million.

What does cash-flow quality show?

Operating cash use improved to $6.6 million in FY2025 from $12.9 million in FY2024, but the business is not self-funding. Spending continues on scientists, laboratories, trials, regulation, and public-company infrastructure. Capital expenditure is modest relative to the larger problem: operating burn between milestone receipts.

How should capital allocation be judged?

Capital allocation balances platform work, EVX-01 follow-up, EVX-04 clinical entry, infectious-disease validation, and runway. Evaxion pays no dividend and is not positioned for buybacks. Partner-funded programs preserve cash; wholly owned programs preserve upside but require more capital. Equity facilities and warrants add flexibility at the cost of potential dilution.

What opportunities and risks could change the story?

A few events can materially change Evaxion’s outlook. Positive EVX-01 durability, EVX-04 clinical entry, another license, or Gates Foundation progress could strengthen platform credibility. Disappointing data, regulatory delays, or a long gap between partner payments would pressure valuation and financing terms.

Which opportunities are most concrete?

Which risks are most material?

Which KPIs best explain Evaxion’s progress?

Traditional revenue growth and earnings-per-share measures are insufficient for a clinical-stage biotechnology company. The most useful KPI set combines biological validation, clinical execution, partnership conversion, spending discipline, and liquidity. These metrics allow a student or analyst to connect scientific progress to future cash-flow potential.

What should be monitored next?

The best monitoring sequence is scientific evidence first, financing second, and accounting revenue third. A strong milestone payment without stronger biological evidence may improve liquidity but not necessarily long-term product probability. Conversely, compelling data without enough cash can still force dilution before value is fully recognized.

What is the key takeaway for valuation and research?

Evaxion does not fit a mature-company DCF. FY2025 revenue reflected a license event, Q1 2026 revenue was zero, and operating cash flow remains negative. A better model separates collaboration revenue from candidate milestones and royalties, applies clinical-stage probabilities, and includes future financing.

Which valuation drivers matter most?